Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Helping smokers quit through pharmacogenetics.

Caryn Lerman1

  • 1Department of Psychiatry and the Annenberg Public Policy Center, University of Pennsylvania, USA.

LDI Issue Brief
|July 11, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Faster CYP2A6 increases COPD and lung cancer risk by increasing smoking quantity: a mediated mendelian randomization and observational mediation study.

Respiratory research·2026
Same author

Reduced cortical complexity in ventromedial prefrontal cortex is associated with a greater preference for risky and immediate rewards.

Imaging neuroscience (Cambridge, Mass.)·2025
Same author

A multi-site study examining the tobacco withdrawal trajectory in people with tobacco and cannabis co-use.

Drug and alcohol dependence·2025
Same author

Secondary Lung Cancer among Survivors of Adolescent and Young Adult Cancer: A Population-Based Study.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2025
Same author

MammaTrace - a cell-free DNA methylation plasma only assay for minimal residual disease detection in breast cancer patients.

medRxiv : the preprint server for health sciences·2025
Same author

Sex dependent genetic architecture of biochemically verified tobacco use.

Psychiatry research·2025
Same journal

The Current State of Evidence on Bundled Payments.

LDI issue brief·2018
Same journal

State-Based Marketplaces Outperform Federally-Facilitated Marketplaces.

LDI issue brief·2018
Same journal

Exploring the decline of narrow networks on the 2017 ACA marketplaces.

LDI issue brief·2017
Same journal

Narrow Networks on the Individual Marketplace in 2017.

LDI issue brief·2017
Same journal

Stabilizing individual health insurance markets with subsidized reinsurance.

LDI issue brief·2017
Same journal

Issue at the Heart of Advancing the De-Adoption of Low-Value Care. Proceedings from an expert roundtable.

LDI issue brief·2017
See all related articles

A new FDA-approved drug, varenicline, offers smoking cessation support. Research explores genetic factors to improve treatments for tobacco dependence, aiming to help more smokers quit long-term.

Area of Science:

  • Public Health
  • Pharmacology
  • Genetics

Background:

  • Smoking remains a leading preventable cause of death in the U.S., with nearly 45 million smokers, many desiring to quit.
  • Current smoking cessation pharmacotherapies, including nicotine replacement therapies (NRTs), bupropion, and the newly approved varenicline, have limited long-term success rates, aiding only about 25% of smokers.
  • Understanding the neurobiology of nicotine addiction and genetic influences is crucial for developing more effective tobacco dependence treatments.

Purpose of the Study:

  • To review ongoing research at Penn's Transdisciplinary Tobacco Use Research Center (TTURC).
  • To investigate genetic factors influencing smoking cessation success.
  • To inform the development of improved smoking cessation strategies.

Main Methods:

Related Experiment Videos

  • Review of current scientific literature on smoking cessation pharmacotherapy.
  • Exploration of genetic research related to nicotine addiction and treatment response.
  • Analysis of ongoing research initiatives at a transdisciplinary tobacco use research center.

Main Results:

  • Varenicline is a new FDA-approved medication for smoking cessation.
  • Existing treatments achieve limited long-term success rates.
  • Genetic and neurobiological research shows promise for future treatment advancements.

Conclusions:

  • Despite new medications like varenicline, significant improvements in long-term smoking cessation rates are needed.
  • Further research into the genetic underpinnings of tobacco dependence is essential.
  • Developing personalized and more effective smoking cessation strategies holds great potential.